Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to 0.32%.

  • Kymera Therapeutics' Return on Capital Employed fell 900.0% to 0.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.32%, marking a year-over-year decrease of 900.0%. This contributed to the annual value of 0.37% for FY2024, which is 400.0% down from last year.
  • Kymera Therapeutics' Return on Capital Employed amounted to 0.32% in Q3 2025, which was down 900.0% from 0.33% recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Return on Capital Employed ranged from a high of 0.13% in Q1 2021 and a low of 0.37% during Q3 2023
  • Over the past 5 years, Kymera Therapeutics' median Return on Capital Employed value was 0.29% (recorded in 2022), while the average stood at 0.27%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -1400bps in 2022, then surged by 1400bps in 2024.
  • Kymera Therapeutics' Return on Capital Employed (Quarter) stood at 0.19% in 2021, then tumbled by -55bps to 0.29% in 2022, then fell by -18bps to 0.35% in 2023, then increased by 19bps to 0.28% in 2024, then dropped by -14bps to 0.32% in 2025.
  • Its last three reported values are 0.32% in Q3 2025, 0.33% for Q2 2025, and 0.31% during Q1 2025.